Navigation Links
Genetic test results for Lynch syndrome improved with new computer program
Date:11/1/2012

SALT LAKE CITYMany patients who have genetic testing for Lynch syndrome, a hereditary predisposition to colon cancer, receive the inconclusive result "variants of uncertain clinical significance." This can be a problem, as people with Lynch syndrome have a much higher probability to develop colon cancer, and often develop colon cancer at an earlier age than is common among the general population; consequently, they need to begin screening at a much younger age.

Now, between two-thirds and three-fourths of these genetic variants can be classified into categories that indicate the most appropriate screening and treatment guidelines, according to two complementary papers published in this month's Human Mutation Early View e-publication. The two papers, both co-authored by Sean Tavtigian, Ph.D., a Huntsman Cancer Institute (HCI) investigator and associate professor in the Department of Oncological Sciences at the University of Utah, provide a model that could help physicians as they assess their patient's risk to develop cancer.

According to the American Cancer Society, about 143,460 new cases of colon cancer will be diagnosed in the United States this year. The National Cancer Institute estimates that two to four percent of all colon cancer is attributable to Lynch syndrome.

Mutations in mismatch repair genes, which proofread DNA to correct genetic typos that occur during the replication process, are known to be the cause of the syndrome. "Some people in families with Lynch syndrome have already known mutations, and a small number of missense substitutions have also been classified as pathogenic," said Tavtigian. "But a fair number have other missense substitutions for which the clinical significance could not be determined, creating uncertainty concerning proper screening and treatment for patients and physicians alike."

The first of the two studies reported on standardizing several already available computer programs that grade the severity of missense substitutions (at the genomic level, these mutations affect only a single structural unit of DNA rather than an entire gene; at the protein level, they affect only a single amino acid rather than the entire protein). The second describes how clinical data concerning the tumors, family history, and other factors were combined with that initial information about severity. Taken together, the procedures described in the two papers allow previously unclassified genetic variations to be assessed for the level of risk they pose in colon cancer development.

"Using these tools, we can evaluate any particular missense substitution and come up with a percentage indicating the probability that it is pathogenic," said Tavtigian. "I'm very careful to avoid saying pathogenic or neutral as an either-or statement. With missense substitutions, I don't believe in a binary classification." A scale developed by his team in 2008 indicates the appropriate level of clinical action for a given percentage of risk, he adds.

Tavtigian is senior author on the first study. Amanda B. Spurdle, Ph.D., associate professor of molecular cancer epidemiology at the Queensland Institute of Medical Research, Brisbane, Australia, is senior author of the second paper, and Tavtigian is a co-principal investigator.

As a result of this research, HCI now has a Web site that physicians, researchers, and even the public can use to look up the probability that a missense substitution in any of the four colon cancer mismatch repair genes is pathogenic. In the future, HCI plans to develop a "suite of Web sites dedicated to unclassified variants in many clinically important cancer susceptibility genes," according to Tavtigian.


'/>"/>

Contact: Linda Aagard
801-587-7639
University of Utah Health Sciences
Source:Eurekalert

Related medicine news :

1. IU researchers report first effective treatment of tumors arising from common genetic disease NF1
2. Smoking and hyperactivity share common genetic risk factor
3. Moffitt Researchers find genetic predictors of fatigue for some prostate cancer patients
4. CWRUs Maxwell J. Mehlmans book examines issues emerging in genetic engineering
5. Genetically-engineered preclinical models predict pharmacodynamic response
6. Scientists Map Genetic Blueprint of Heart
7. Epigenetics emerges powerfully as a clinical tool
8. Parents of babies with sickle cell trait are less likely to receive genetic counseling, study says
9. How genetics shape our addictions
10. Researchers find first evidence for a genetic cause for Barretts esophagus
11. Genetics Society of Americas Genetics journal highlights for September 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... Houston, Texas (PRWEB) , ... May 03, 2016 ... ... company, today announced that it is launching a new client service center in ... in Houston, Texas, and will provide the full range of Empyrean client services. ...
(Date:5/3/2016)... ... ... Park Cities Pet Sitter has openings for both full-time and part-time pet ... 75220, 75225, 75229, 75230, 75231 and 75235 zip codes. These zip codes are ... Park Cities areas of the Metroplex. Candidates must love animals, have attention to ...
(Date:5/3/2016)... ... 03, 2016 , ... For the sixth consecutive year, Crawford ... (ICT) companies in the annual Branham300 listing. For 23 years, the Branhan300 has ... by revenue. , “We are honored to be on the Branham300 list ...
(Date:5/3/2016)... NJ (PRWEB) , ... May 03, 2016 , ... ... the general availability of the latest release of DocAve 6 Service Pack ... AvePoint helps organizations migrate to SharePoint 2016 and take advantage of the platform’s ...
(Date:5/3/2016)... City, UT (PRWEB) , ... May 03, 2016 , ... ... Utah, recently announced that its Allegro Anti-aging Cream, a revolutionary new anti-aging skin ... signs of aging and repair damaged skin, has sold over seventy-five thousand units worldwide ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... from Sino-German High-Tech Fund to further expand product development, strengthen its disease modeling capabilities and increase market presence. ... ... ... ... Sino-German High-Tech ...
(Date:5/3/2016)... , May 3, 2016   BIOTRONIK , ... today announced Food and Drug Administration (FDA) approval ... that provides heart failure patients with access to ... also have remote monitoring with daily automatic transmission ... heart rate in response to physiological demands. ...
(Date:5/3/2016)... , May 3, 2016   Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today that it is ... a video of two patients who tell their personal story and encourage those at risk ... Meet Jacque: Hepatitis C ... ... Diplomat Specialty Pharmacy (PRNewsFoto/Diplomat Pharmacy, Inc.) ...
Breaking Medicine Technology: